Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 4Liver Neoplasms 2Thyroid Neoplasms 1Spinal Cord Compression 1Sarcoma 1Recurrence 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Melanoma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

Oxaliplatin 10Gemcitabine 8Cisplatin 7Hepatectomy 6Fluorouracil 6Radiofrequency Ablation 5Liver Transplantation 5Irinotecan 5Capecitabine 5lenvatinib 4Paclitaxel 4Neoadjuvant Therapy 4Folfox protocol 4Cetuximab 4Aspirin 4tislelizumab 3Surgical Procedures, Operative 3Nivolumab 3Carboplatin 3titanium silicide 2durvalumab 2apatinib 2Trastuzumab 2S 1 (combination) 2Leucovorin 2Lamivudine 2Introns 2Ethiodized Oil 2Drug Therapy 2DNA, Mitochondrial 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Transurethral Resection of Prostate × Gastrointestinal × Clear all
NCT06609876 2024-12-03

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

Sun Yat-sen University

Phase NA Recruiting
108 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡